Table of Contents: CATIE TreatmentUpdate - 2001


Canadian AIDS Treatment Information Exchange
Edited by: Sean Hosein

Jump to Table of Contents

TreatmentUpdate 119: July - Vol. 13, No. 3

English  Françaises

 Fosamax for HIV-related bone problems?

 Fosamax pour les problèmes d'os liés au VIH

HoseinSR
People with HIV/AIDS (PHAs) who use corticosteroids and/or anti-HIV therapy may be at increased risk for the development of thinner, more porous bones — a condition called osteoporosis. As bones become thinner they can easily break or fracture. The best course of action to prevent and treat osteoporosis in PHAs is not yet clear and researchers are experimenting with different strategies. In a letter published in the August 1, 2001 issue of the journal Clinical Infectious Diseases, researchers in Italy reported that the bone-building treatment Fosamax (alendronate) has helped one PHA recover from osteoporosis. We now report the details of their report.

 Indinavir and bones: Does thickness = strength?

 L'indinavir et les os — la force réside-t-elle dans l'épaisseur?

HoseinSR
Why these problems occur is not clear. Some researchers suspect that the components of HAART — protease inhibitors, nukes and/or non-nukes — and even HIV infection may all play a role.

 Lipodystrophy — nukes vs. protease inhibitors

 La lipodystrophie — les analogues nucléosidiques contre les inhibiteurs de la protéase

HoseinSR
In the late 1990s, people with HIV/AIDS (PHAs) using HAART began to report strange changes in body shape. There were also reports of increased levels of sugar, insulin and fatty substances in the blood of PHAs. These changes increased the risk of non-insulin-dependent diabetes and cardiovascular disease, among other complications. Together, these changes have been called the lipodystrophy syndrome.

 Spanish study looks at nevirapine's effect on the liver

 Des chercheurs espagnols évaluent l'effet de la névirapine sur le foie

HoseinSR
Doctors in Spain analysed data from 610 subjects who were using nevirapine (Viramune)-containing regimens. The purpose of the study was to find out about nevirapine's impact on the liver. To do this, technicians regularly tested blood samples from study subjects checking for liver enzyme levels.

 Pesticides found in many ginseng supplements in the U.S.

 Les autorités américaines découvrent des pesticides dans plusieurs suppléments de ginseng

HoseinSR
The organization ConsumerLab in the U.S. conducts independent testing of supplements sold in that country. The purpose of the testing is to find out if the ingredients listed on the label match those found in the capsules, tablets or liquids that accompany the label. The company produces reports which are available on its website at www.consumerlab.com.

 Can ginseng help suppress HIV?

 Le ginseng peut-il supprimer le VIH?

HoseinSR
The roots of the ginseng plant have been used for centuries by herbalists because of its anti-stress and anti-fatigue effects. Researchers in Hong Kong have been studying this herb and found that ginseng contains a protein called panaxagin which has anti-HIV activity in the test-tube. This protein appears to work by interfering with an enzyme used by HIV called RT (reverse transcriptase). This is the same enzyme that is attacked by AZT and other nucleoside analogues, or nukes, such as 3TC (lamivudine, Epivir), d4T, ddI, ddC and ABC (abacavir, Ziagen).

 Large Italian study looks at when to start HAART

 Une grande étude italienne examine le moment d'amorcer la multithérapie

HoseinSR
Recent revisions to North American HIV treatment guidelines have taken a more cautious approach to the timing of treatment.

Table Of Contents

TreatmentUpdate 123: November/December - Vol. 13, No. 7
Can delavirdine substitute for ritonavir?; Hepatitis C treatment, HAART and side effects; Toxicity profile of HAART; Rosiglitazone for lipodstrophy?; Actos (pioglitazone); Focus on fat; Metformin — long-term results; Sugar blues and protease inhibitors; Glucose — from food to blood sugar; Lipodystrophy - introduction; Caution with nelfinavir and some lipid-lowering drugs; Trizivir approved in Canada;

TreatmentUpdate 122: October - Vol. 13, No. 6
Looking at soluble CD23 levels to predict lymphoma; Cidofovir for KS lesions; Can low-dose shark cartilage make Kaposi's sarcoma disappear?; Chemo and HAART extend survival with lymphoma; Encouraging news on lymphoma from France; AIDS and lymphoma; New formulation of ddI approved in Canada — Videx EC; Expanded access to tenofovir

TreatmentUpdate 121: September - Vol. 13, No. 5
SIDE EFFECTS - Andractim for HAART-associated breast enlargement; SIDE EFFECTS - Does efavirenz cause breast enlargement?; IMMUNE BOOSTERS - Interleukin-12 may be useful for hepatitis C; ANTI-HIV AGENTS - Study finds HIV subtly damages vision; ANTI-HIV AGENTS - Searching for the right dose of ritonavir-saquinavir; ANTI-HIV AGENTS - Different combinations of ritonavir-indinavir

TreatmentUpdate 120: August - Vol. 13, No. 4
Depression linked to immune system decline in women; Carnitine for high triglycerides; Lipid-lowering drugs and changes to diet can make a difference; Sexual dysfunction and HAART; Immune booster used to fight drug-resistant herpes; Effect of HAART on cervical growths; Switching to nevirapine — results after one year

TreatmentUpdate 119: July - Vol. 13, No. 3
Fosamax for HIV-related bone problems?; Indinavir and bones: Does thickness = strength?; Lipodystrophy — nukes vs. protease inhibitors; Spanish study looks at nevirapine's effect on the liver; Pesticides found in many ginseng supplements in the U.S.; Can ginseng help suppress HIV?; Large Italian study looks at when to start HAART;

TreatmentUpdate 118: June - Vol. 13, No. 2
Protease inhibitors and blood sugar problems; Indinavir - effect on sugar and insulin; Background on glucose — from food to blood sugar; Extra co-enzyme Q10 for statin-users?; Can vitamin E help people recover from hepatitis B?; Study examines link between low levels of zinc and survival; Zinc and the immune system;

TreatmentUpdate 117: May - Vol. 13, No. 1
Bone damage - more than just nukes involved; Australian study links nukes, lactic acid to bone loss;High levels of lactic acid in some users of HAART ;Nukes may be linked to hearing loss; Of power plants and energy shortages; German study finds whey protein supplement boosts antioxidants; Spanish doctors try switching therapy from month to month

TreatmentUpdate 115: February - Vol. 12, No. 11
St. John's wort found to lower nevirapine levels; Are deaths due to liver damage becoming more common?; St. John's wort extract found not helpful for hepatitis C; Canadian researchers study "immune healing"; Kaletra approved in Canada;

TreatmentUpdate 114: January - Vol. 12, No. 10
Some women may be at high risk for anal cancer; DHEA — Cautions and concerns; DHEA for depression?; Changes in DHEA levels in people taking anti-HIV therapy; DHEA — Background; Nukes linked to fat wasting; Triple nuke therapy — results after one year; Switching meds: from protease inhibitors to non-nukes

Copyright / Staff / How to Contact
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2000. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.